@article{0620215b637d4ad4aaa749a98067a965,
title = "Sex differences in response to citalopram: A STAR*D report",
abstract = "Objective: Controversy exists as to whether women with depression respond better to selective serotonin reuptake inhibitors (SSRIs) than men. The purpose of this report was to determine whether men and women differ in their responses to treatment with the SSRI citalopram using a large sample of real world patients from primary and psychiatric specialty care settings. Method: As part of the sequenced treatment alternatives to relieve depression (STAR*D) study, 2876 participants were treated with citalopram for up to 12-14 weeks. Baseline demographic and clinical characteristics and outcomes were gathered and compared between men and women. Results: At baseline, women were younger, had more severe depressive symptoms and were more likely to have: early onset; previous suicide attempt(s); a family history of depression, alcohol abuse or drug abuse; atypical symptom features; and one or more of several concurrent psychiatric disorders. Despite greater baseline severity and more Axis I comorbidities, women were more likely to reach remission and response with citalopram than men. Conclusions: Women have a better response to the SSRI citalopram than men, which may be due to sex-specific biological differences particularly in serotonergic systems.",
keywords = "Antidepressants, Depression, Estradiol, Gender differences, Women's health",
author = "Young, {Elizabeth A.} and Kornstein, {Susan G.} and Marcus, {Sheila M.} and Harvey, {Anne T.} and Diane Warden and Wisniewski, {Stephen R.} and Balasubramani, {G. K.} and Maurizio Fava and Trivedi, {Madhukar H.} and {John Rush}, A.",
note = "Funding Information: M. Fava has received research support from: Abbott Laboratories, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, J & J Pharmaceuticals, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, Novartis, Organon Inc., PamLab, LLC, Pfizer Inc, Pharmavite, Roche, Sanofi/Synthelabo, Solvay Pharmaceuticals Inc., Wyeth-Ayerst Laboratories. He has an Advisory/Consulting relationship with: Aspect Medical Systems, Astra-Zeneca, Bayer AG, Auspex Pharmaceuticals, Best Practice Project Management Inc. Biovail Pharmaceuticals Inc., BrainCells Inc. Bristol-Myers Squibb Company, Cephalon, Compellis, CNS Response, Cypress Pharmaceuticals, Dov Pharmaceuticals, Eli Lilly & Company, EPIX Pharmaceuticals, Fabre-Kramer Pharmaceuticals Inc., Forest Pharmaceuticals Inc., GlaxoSmithkline, Grunenthal GmBH, Janssen Pharmaceutica, Jazz Pharmaceuticals, J&J Pharmaceuticals, Knoll Pharmaceutical Company, Lundbeck, MedAvante Inc., Merck, Neuronetics, Novartis, Nutrition 21, Organon Inc., PamLab, LLC, Pfizer Inc, PharmaStar, Pharmavite, Precision Human Biolaboratory, Roche, Sanofi/Synthelabo, Sepracor, Solvay Pharmaceuticals Inc., Somaxon, Somerset Pharmaceuticals, Takeda, TetraGenex Inc., Transcept Pharmaceuticals, Wyeth-Ayerst Laboratories. He is a speaker for: Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers Squibb Company, Cephalon, Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithkline, Novartis, Organon Inc., Pfizer Inc, PharmaStar, Wyeth-Ayerst Laboratories He has Equity Holdings: Compellis, MedAvante. He has no patent income. Funding Information: This project was funded by the National Institute of Mental Health under Contract N01MH90003 to UT Southwestern Medical Center at Dallas (P.I.: A.J. Rush). NIMH played no role in data analysis nor in drafting of the manuscript but participated in discussions of study design and conduct. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Funding Information: A.J. Rush has provided scientific consultation to or served on Advisory Boards for Advanced Neuromodulation Systems, Inc., Best Practice Project Management, Inc., Bristol-Myers Squibb Company, Cyberonics Inc., Eli Lilly & Company, Forest Pharmaceuticals Inc., Gerson Lehman Group, GlaxoSmithKline, Healthcare Technology Systems, Inc., Jazz Pharmaceuticals, Merck & Co. Inc., Neuronetics, Ono Pharmaceuticals, Organon USA Inc., Personality Disorder Research Co., Pfizer Inc., the Urban Institute, and Wyeth-Ayerst Laboratories Inc. He has received royalties from Guilford Press and Healthcare Technology Systems and research/grant support from the Robert Wood Johnson Foundation, the National Institute of Mental Health, and the Stanley Medical Research Institute. He has been on speaker bureaus for Cyberonics, Inc., Eli Lilly & Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, and Merck & Co. Inc., and owns stock in Pfizer Inc. Funding Information: Madhukar H. Trivedi, M.D has been a consultant for: Abbott Laboratories Inc.; Akzo (Organon Pharmaceuticals Inc.); Astra-Zeneca; Bayer; Bristol-Myers Squibb Company; Cephalon Inc.; Cyberonics Inc.; Eli Lilly & Company; Fabre-Kramer Pharmaceuticals, Inc. Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Johnson & Johnson PRD; Eli Lilly & Company; Meade Johnson; Neuronetics; Parke-Davis Pharmaceuticals Inc.; Pfizer Inc.; Pharmacia & Upjohn; Sepracor; Solvay Pharmaceuticals Inc.; VantagePoint; and Wyeth-Ayerst Laboratories. He has served on speakers bureaus for Abdi Brahim; Akzo (Organon Pharmaceuticals Inc.); Bristol-Myers Squibb Company; Cephalon Inc.; Cyberonics Inc.; Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Eli Lilly & Company; Pharmacia & Upjohn; Solvay Pharmaceuticals Inc.; and Wyeth-Ayerst Laboratories. He has also received grant support from Bristol-Myers Squibb Company; Cephalon Inc.; Corcept Therapeutics Inc.; Cyberonics Inc.; Eli Lilly & Company; Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica; Merck; National Institute of Mental Health; National Alliance for Research in Schizophrenia and Depression; Novartis; Pfizer Inc.; Pharmacia & Upjohn; Predix Pharmaceuticals; Solvay Pharmaceuticals Inc.; and Wyeth-Ayerst Laboratories. Funding Information: S.G. Kornstein has received research support from Department of Health and Human Services, National Institute of Mental Health, Pfizer Inc., Bristol-Myers Squibb Company, Lilly Inc., Forest Laboratories Inc., GlaxoSmithKline Inc., Mitsubishi-Tokyo, Merck Inc., Biovail Laboratories Inc., Wyeth Inc., Berlex Laboratories, Novartis Pharmaceuticals Inc., Sepracor Inc., Boehringer-Ingelheim, Sanofi-Synthelabo, and Astra-Zeneca. She has provided scientific consultation to or served on Advisory Boards for Pfizer Inc., Wyeth Inc., Lilly Inc., Bristol-Myers Squibb Company, Warner-Chilcott Inc., Biovail Laboratories, Berlex Laboratories, Neurocrine, Sepracor, and Forest Laboratories. She has received royalties from Guilford Press. ",
year = "2009",
month = feb,
doi = "10.1016/j.jpsychires.2008.07.002",
language = "English (US)",
volume = "43",
pages = "503--511",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",
number = "5",
}